Mirum Pharmaceuticals, Inc. (MIRM) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Foster City, CA, アメリカ. 現CEOは Christopher Peetz.
MIRM を有する IPO日 2019-07-18, 334 名の正社員, に上場 NASDAQ Global Market, 時価総額 $4.86B.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for rare and orphan diseases affecting the liver and bile system. The company's lead product candidate, LIVMARLI, is an investigational oral medication designed to treat progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. Mirum also develops Volixibat for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018 and headquartered in Foster City, California, Mirum focuses on addressing critical unmet needs in hepatobiliary diseases.
